Clay Siegall Expects Seattle Genetics To Continue Creating Effective Anti-Cancer Solutions

Clay Siegall has worked since 1998 to formulate antibodies into therapies that destroy cancer cells from within. Seattle Genetics is his company, and it is valued at close to $10 billion and has 900 employees on its payroll. The company’s main drug is called Adcetris, and it works to treat Hodgkin lymphoma, which is a cancer that effects the lymphatic system with abilities to spread to other organs in the body. As the company grows, Siegall focuses on making it a global company and is working with his team to market it to the international community. Part of the moves he is making includes spending $2 billion to gain access to global rights to market a cancer drug. Unfortunately this fell threw, but he isn’t giving up.

Seattle Genetics, under Clay Siegall’s careful guidance, has been growing steadily and made $418 million in sales in 2016. The company increased research funding recently and has been focusing a lot of its efforts on antibody-drug conjugates (ADC’s), which can attach themselves to cancer cells and inject toxins inside of them that kill the cells. The amazing thing about this solution is that it does not cause damage to surrounding healthy cells like so many other medical solutions do. Four of the drugs that Seattle Genetics is working on have huge potential, and Adcetris is the most popular of them. It is expected that Adcetris could become an important drug for oncologists and that this would greatly increase the company’s income.

Clay Siegall is the co-founder, CEO, Chairman of the Board, and President of Seattle Genetics and has been so since 1998. He helped to build the company from the ground-up and used his own experience and training as a scientist to do so. It was when he helped to develop antibody-drug conjugates that led to the FDA approved product named ADCETRIS that the company really began to take off. Some of the newer antibody-drug conjugates that Siegall is working on are aimed at treating cancer.

Clay Seigall worked with the National Cancer Institute and the National Institutes of Health near the earlier part of his working career, and he also worked with the Bristol-Myers Squibb

Pharmaceutical Research Institute after that. A couple of the awards he has won include the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year and the 2013 University of Maryland Alumnus of the Year for Computer, Math, and Natural Sciences. Siegall earned his Bachelor’s of Science Degree in Zoology while attending the University of Maryland and received his Ph.D. in Genetics while studying at George Washington University.

Leave a Reply

Your email address will not be published. Required fields are marked *